Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis

Aldo J Montano-Loza, Paul Angulo, Judith Meza-Junco, Carla M M Prado, Michael B Sawyer, Crystal Beaumont, Nina Esfandiari, Mang Ma, Vickie E Baracos, Aldo J Montano-Loza, Paul Angulo, Judith Meza-Junco, Carla M M Prado, Michael B Sawyer, Crystal Beaumont, Nina Esfandiari, Mang Ma, Vickie E Baracos

Abstract

Background and aims: Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients.

Methods: We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body mass index-specific cutoffs.

Results: Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%), alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353 had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months, P < 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22 months, P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months, P < 0.001) had worse median survival than patients without muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.44-2.77, P < 0.001], and myosteatosis (HR 1.42, 95% CI 1.02-1.07, P = 0.04) were associated with mortality.

Conclusions: Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia and myosteatosis are independently associated with a higher long-term mortality in cirrhosis.

Keywords: Cirrhosis; Lumbar skeletal muscle index; Muscle attenuation index; Muscle depletion; Myosteatosis; Overweight.

Figures

Figure 1
Figure 1
Venn diagram illustrating the association between sarcopenia, myosteatosis and obesity.
Figure 2
Figure 2
Computed tomography images used for the muscularity assessment of patients with cirrhosis. Comparison of two cirrhotic patients with severe obesity. (A) Male patient at the left had sarcopenic obesity (BMI 47 kg/m2, L3 SMI 51 cm2/m2), whereas a female patient at the right (B) had no sarcopenia (BMI 42 kg/m2, L3 SMI 49 cm2/m2). Computed tomography images used for the muscle attenuation assessment of patients with cirrhosis and comparison of two cirrhotic patients with similar BMI (28 kg/m2). (C) Patient at the left had low mean muscle attenuation (21 HU), whereas the patient at the right (D) had normal mean muscle attenuation (40 HU).
Figure 3
Figure 3
Kaplan–Meier curve indicating the survival of patients with sarcopenia (—), sarcopenic obesity (‐‐), myosteatosis (‐‐) and without muscular abnormalities (—). The 6‐month probability of survival was 72%, 69%, 76% and 91%, respectively (P < 0.001, log‐rank test). The 1‐year probability of survival was 62%, 59%, 68%, and 85% in these same groups, respectively.
Figure 4
Figure 4
Percentage of mortality related to liver failure, sepsis, hepatocellular carcinoma progression, variceal bleeding, hepatorenal syndrome and others in cirrhotic patients with (A) sarcopenia, (B) myosteatosis and (C) sarcopenic obesity. GI, gastrointestinal; HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome.

References

    1. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 2012; 70: 3–21.
    1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132: 2087–102.
    1. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, et al Weight‐related effects on disease progression in the hepatitis C antiviral long‐term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549–57.
    1. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al Risk factors of fibrosis in alcohol‐induced liver disease. Hepatology 2002; 35: 635–8.
    1. Berzigotti A, Garcia‐Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2010; 54: 555–61.
    1. Meza‐Junco J, Montano‐Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol 2013; 47: 861–70.
    1. Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013; 13: 1549–56.
    1. Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19: 1396–402.
    1. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271–8.
    1. Montano‐Loza AJ, Meza‐Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166–73.
    1. Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract 2013; 28: 15–29.
    1. O'Brien A, Williams R. Nutrition in end‐stage liver disease: principles and practice. Gastroenterology 2008; 134: 1729–40.
    1. Montano‐Loza AJ. New concepts in liver cirrhosis: clinical significance of sarcopenia in cirrhotic patients. Minerva Gastroenterol Dietol 2013; 59: 173–86.
    1. Montano‐Loza AJ. Muscle wasting: a nutritional criterion to prioritize patients for liver transplantation. Curr Opin Clin Nutr Metab Care 2014; 17: 219–25.
    1. Masuda T, Shirabe K, Ikegami T, Harimoto N, Yoshizumi T, Soejima Y, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transplant 2014; 20: 401–7.
    1. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroen Hepat 2013; 25: 85–93.
    1. Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60: 1151–7.
    1. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997–1006.
    1. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle 2012; 3: 225–37.
    1. Lang PO, Michel JP, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology 2009; 55: 539–49.
    1. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755–63.
    1. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2010; 21: 543–59.
    1. Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab 2010; 35: 707–12.
    1. Schrager MA, Metter EJ, Simonsick E, Ble A, Bandinelli S, Lauretani F, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol 2007; 102: 919–25.
    1. Kim TN, Park MS, Lim KI, Choi HY, Yang SJ, Yoo HJ, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 2013; 78: 525–32.
    1. Gallagher D, Kuznia P, Heshka S, Albu J, Heymsfield SB, Goodpaster B, et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr 2005; 81: 903–10.
    1. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140–2.
    1. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well‐functioning older persons. J Gerontol A Biol Sci Med Sci 2005; 60: 324–33.
    1. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998; 85: 115–22.
    1. Kvist H, Sjostrom L, Tylen U. Adipose tissue volume determinations in women by computed tomography: technical considerations. Int J Obes 1986; 10: 53–67.
    1. Vehmas T, Kairemo KJ, Taavitsainen MJ. Measuring visceral adipose tissue content from contrast enhanced computed tomography. Int J Obes Relat Metab Disord 1996; 20: 570–3.
    1. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539–47.
    1. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013; 4: 95–109.
    1. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care‐associated bacterial infections. Clin Gastroenterol Hepatol 2010; 8: 979–85.
    1. Owen OE, Reichle FA, Mozzoli MA, Kreulen T, Patel MS, Elfenbein IB, et al Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest 1981; 68: 240–52.
    1. Kondrup J, Nielsen K, Hamberg O. Nutritional therapy in patients with liver cirrhosis. Eur J Clin Nutr 1992; 46: 239–46.
    1. Beyer I, Mets T, Bautmans I. Chronic low‐grade inflammation and age‐related sarcopenia. Curr Opin Clin Nutr Metab Care 2012; 15: 12–22.
    1. Dasarathy S, McCullough AJ, Muc S, Schneyer A, Bennett CD, Dodig M, et al Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol 2011; 54: 915–21.
    1. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH Jr, et al. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 2001; 280: E221–8.
    1. Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, et al. Hyperammonemia‐mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab 2012; 303: E983–93.
    1. Montano‐Loza AJ, Meza‐Junco J, Prado CM, Tandon P, Bain VG, Ma M, et al. New cutoff values for sarcopenia for predicting 6‐months mortality in cirrhotic patients. J Hepatol 2013; 58: S95.
    1. Montano‐Loza AJ, Meza‐Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20: 640–8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する